טוען...
Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML
Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody conjugated with calicheamicin (a cytotoxic antibiotic) that is used for the treatment of acute myeloid leukemia (AML). The relationship between the CD33 expression in leukemic cells and response to GO treatment has been controversial. We studied CD...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2008
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2659556/ https://ncbi.nlm.nih.gov/pubmed/18615103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2008.185 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|